Abstract: The present invention relates to a paclitaxel composition and the preparation methods thereof for the treatment of bladder cancer wherein said paclitaxel composition comprises 4˜90% by weight of at least one selected from the monoglycerides, 0.01˜90% by weight of at least one oil, 0.01˜90% by weight of at least one emulsifier and 0.01˜20% by weight of paclitaxel. The composition of the present invention can treat bladder cancer effectively since the composition solubilizes paclitaxel, does not form aggregates, adsorbs well on the bladder wall and penetrates into the muscle layer of the bladder.

Abstract: The present invention relates to a paclitaxel composition and the preparation methods thereof to solubilize paclitaxel wherein said composition comprises 4˜90% by weight of at least one selected from the monoglycerides, 0.01˜90% by weight of at least one oil and 0.01˜20% by weight of paclitaxel. Also the present invention relates to a paclitaxel composition including emulsifiers and the preparation methods thereof to solubilize paclitaxel wherein said composition comprises 4˜90% by weight of at least one selected from the monoglycerides, 0.01˜90% by weight of at least one oil, 0.01˜90% by weight of at least one emulsifier and 0.01˜20% by weight of paclitaxel. The composition of the present invention is an effective paclitaxel delivery system since the composition solubilizes paclitaxel, does not form aggregates after being dispersed in water, adsorbs well on the intestinal wall, and therefore has high bioavailability.

Abstract: The present invention relates to an anhydrous liquid composition wherein monoglyceride is mixed with an emulsifier and a solvent, and the manufacturing method thereof, and more specifically, to an anhydrous liquid composition wherein monoglyceride is mixed with a water-insoluble material, an emulsifier and a solvent, and the manufacturing method thereof. Further, the present invention relates to a lyophilized powder and the manufacturing method thereof, wherein the lyophilized powder is prepared by dissolving the mixed liquid composition in water, adding with a cryoprotectant followed by the lyophilization. In the process of dispersion, the lyophilized liquid composition and the powder of the present invention can spontaneously generate particles of 200-500 nm by gently shaking with hands without a powerful mechanical force.

Abstract: Oily paclitaxel composition and formulation for chemoembolization and preparation method thereof solubilizing paclitaxel in an oily contrast medium. The composition of the present invention solubilizes paclitaxel and has an advantage of delivering anticancer drug to the target cells by chemoembolization since it is possible to visualize the blood vessel during the chemoembolization process. The present invention also relates to oily paclitaxel composition and formulation additionally comprising chemicals that prevent paclitaxel precipitation for prolonged preservation and the preparation method thereof. Since the composition of the present invention solubilize paclitaxel effectively and can be visualized during chemoembolization, it can be used for TACE to treat hepatoma and other solid tumors.

Abstract: The present invention relates to an anticancer drug-chitosan complex forming self-aggregates and the preparation method thereof. More precisely, the present invention relates to the anticancer drug-chitosan complex forming self-aggregates in aqueous media composed of a hydrophobic anticancer agent and a hydrophilic chitosan, and the preparation method thereof. The anticancer drug-chitosan complex of the present invention not only works selectively against target tumor tissue but also continues to release the medicine over a long period of time. Besides, the anticancer drug-chitosan complex could have greater amount of drug by adding the anticancer drug into self-aggregates, which is generally limited by chemical bond. Therefore, the anticancer drug-chitosan complex of the present invention can be effectively used for the cancer chemotherapy.

Abstract: The present invention relates to macroporous chitosan beads having 5-200 &mgr;m in size of relatively large and uniform pores that are distributed from surface to core region, and a preparation method thereof compring the following steps; by dropping chitosan solution, aqueous chitosan solution or their mixture into the low-temperature of organic solvent or liquid nitrogen; and by regulating pore size by phase separation method via temperature difference.

Abstract: The present invention relates to an anhydrous liquid composition wherein monoglyceride is mixed with an emulsifier and a solvent, and the manufacturing method thereof, and more specifically, to an anhydrous liquid composition wherein monoglyc- eride is mixed with a water-insoluble material, an emulsifier and a solvent, and the manufacturing method thereof. Further, the present invention relates to a lyophilized powder and the manufacturing method thereof, wherein the lyophilized powder is prepared by dissolving the mixed liquid composition in water, adding with a cryoprotectant followed by the lyophilization. In the process of dispersion, the lyophilized liquid composition and the powder of the present invention can spontaneously generate particles of 200-500 nm by gently shaking with hands without a powerful mechanical force.

Abstract: A method of manufacturing a porous matrix-type drug delivery system is provided. It comprises the steps of: dispersing, stirring, and emulsifying an aqueous solution of a drug in an organic solvent having a polymer compound and a surface active agent solved therein; thereafter forming it into a desirable matrix shape; lyophilizing or drying it at a low temperature or room temperature until the matrix surface is hardened; and drying it again in order to remove the water and the organic solvent.

Abstract: A preparation method for biodegradable polymeric microspheres using a solvent extraction method for biodegradable polymeric microspheres for treating a local inflammation disease using the same which are capable of effectively curing ozena such as sinusitis and a middle ear infection. Since a non-solvent of polymer is added into an outer aqueous phase in advance, the solidification of the polymer is implemented in a short time which, in turn, improves encapsulation of the therapeutic agent used.

Abstract: Novel sulfonated polyethyleneoxide-substituted polymers having improved blood compatibility are provided. The polymers are produced by substituting a polymeric substrate having active sites of amide or acid amide group, such as polyurethane, polyamide and polyacrylamide, with sulfonated polyethyleneoxide [PEO--(SO.sub.3 H).sub.n ].The polymers according to the present invention are valuable as construction materials of the artificial organs for the circulatory system in contact with blood, such as artificial hearts, artificial blood vessels, artificial kidneys, etc.

Abstract: Novel sulfonated polyethyleneoxide-substituted polymers having improved blood compatibility are provided. The polymers are produced by substituting a polymeric substrate having active sites of amide or acid amide group, such as polyurethane, polyamide and polyacrylamide, with sulfonated polyethyleneoxide PEO-SO.sub.3 H.The polymers according to the present invention are valuable as construction materials of the artificial organs for the circulatory system in contact with blood, such as artificial hearts, artificial blood vessels, artificial kidneys, etc.